{"id":481621,"date":"2021-04-26T08:48:45","date_gmt":"2021-04-26T12:48:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-introduces-hfx-new-comprehensive-brand-identity-combining-nevros-innovative-technologies-advanced-therapies-and-end-to-end-patient-support\/"},"modified":"2021-04-26T08:48:45","modified_gmt":"2021-04-26T12:48:45","slug":"nevro-introduces-hfx-new-comprehensive-brand-identity-combining-nevros-innovative-technologies-advanced-therapies-and-end-to-end-patient-support","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-introduces-hfx-new-comprehensive-brand-identity-combining-nevros-innovative-technologies-advanced-therapies-and-end-to-end-patient-support\/","title":{"rendered":"Nevro Introduces HFX, New Comprehensive Brand Identity Combining Nevro’s Innovative Technologies, Advanced Therapies and End-to-End Patient Support"},"content":{"rendered":"
\n

Company Announces Full U.S. Market Launch of Recent Omnia\u2122 Upgrade, Now HFX Connect\u2122<\/h2>\n

Upgrade Facilitates Remote Therapy Optimization for Individualized Relief from Chronic Pain Based on Real-World Data<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n REDWOOD CITY, Calif.<\/span>, April 26, 2021<\/span> \/PRNewswire\/ —\u00a0Nevro Corp.\u00a0(NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today \u00a0announced the introduction of its new HFX brand and updated website, which is designed to unify its products and services to optimize the physician and patient experience. \u00a0The introduction of the HFX brand platform includes the full U.S. market launch of the company’s recent Omnia upgrade (powered by HFX Connect) and additional patient support resources (HFX Coach\u2122<\/span>, formerly called Therapy Support Specialists) who are trained in remote therapy optimization.\u00a0 <\/p>\n

“Today we are known for our highly differentiated SCS products, but the value our technology provides to patients and customers is really far greater,” said Niamh Pellegrini<\/span>, Chief Commercial Officer of Nevro.\u00a0 “Under our new HFX brand identity, we will be able to bring products, services and support together under one cohesive, durable framework that supports today’s solutions and tomorrow’s new offerings, whether they are new products, innovations in waveforms and frequencies, services, clinical data, or our unique forms of patient and customer support.”<\/p>\n

HFX\u00a0gives Nevro the ability to bring together\u00a0its\u00a0innovative technologies, advanced therapies and end-to-end support services, all of which are\u00a0built on an industry-leading foundation of robust clinical data.\u00a0 For physicians, HFX technologies and advanced therapies offer\u00a0the broadest range of frequencies and waveforms, including Nevro’s proprietary 10 kHz therapy,\u00a0which has demonstrated superior back and leg pain relief versus traditional spinal cord stimulation (SCS) and is the most studied waveform in the industry.\u00a0\u00a0<\/p>\n

“The Omnia upgrade, now powered by HFX Connect, has enhanced my ability to remotely support patients, especially during the pandemic,” said Bryan C. Hoelzer<\/span>, MD, anesthesiologist, pain specialist and former Director of Neuromodulation and the Pain Medicine Fellowship at the Mayo Clinic in Rochester.\u00a0 “It includes more customizable programs and a richer approach to optimizing therapy that is informed by Nevro’s large patient database. It has helped me reliably get relief for my patients.”<\/p>\n

\n HFX Connect: Continuing Innovation for Individualized Therapy and Patient Support<\/b>\n <\/p>\n

Omnia powered by HFX Connect, provides the widest array of SCS frequencies and waveforms, which can now also be delivered remotely by HFX Coaches to meet every patient’s needs. \u00a0HFX Connect is universally compatible with both new and previously implanted Omnia systems. <\/p>\n